← Idorsia Pharmaceuticals Ltd. (IDIA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Idorsia Pharmaceuticals Ltd. (IDIA)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-27 (est.)
PDUFA
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-12-27 (est.)PDUFA · BOND-003imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Daridorexant 10 mg | Phase 3 | Insomnia Disorder |
| ACT-541468 5 mg | Phase 2 | Insomnia Disorder |
| ACT-709478 for oral use | Phase 2 | Photosensitive Epilepsy |
| Aprocitentan 5 mg | Phase 2 | Essential Hypertension |
| Clazosentan 1 mg/h | Phase 2 | Aneurysmal Subarachnoid Hemorrhage |
| ACT-541468 | Phase 2 | Insomnia Disorder |
| ACT-774312 | Phase 2 | Bilateral Nasal Polyposis |
| ACT-280778 | Phase 2 | Essential Hypertension |
| Daridorexant | Phase 3 | Insomnia Disorder |
| Cetirizine | Phase 3 | Seasonal Allergic Rhinitis |
| ACT-539313 | Phase 2 | Binge-Eating Disorder |
| Aprocitentan 12.5 mg | Phase 3 | Resistant Hypertension |
| Lucerastat | Phase 3 | Fabry Disease |
| Clazosentan | Phase 3 | Aneurysmal Subarachnoid Hemorrhage |
| tezosentan | Phase 3 | Acute Heart Failure |
| Setipiprant | Phase 2 | Asthma |
| Daridorexant 50 mg | Phase 3 | Insomnia Disorder |
| Zolpidem | Phase 2 | Insomnia Disorder |
| Daridorexant 25 mg | Phase 3 | Insomnia |
| ACT-129968 | Phase 3 | Seasonal Allergic Rhinitis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IDIA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.